[CAS NO. 2436747-41-8] BB-Cl-Amidine hydrochloride
PRODUCTS SPECIFICATIONS [2436747-41-8]
DESCRIPTION [2436747-41-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 496.43 |
| Molecular Formula | C26H27Cl2N5O |
| SMILES | O=C(C1=CC=C(C2=CC=CC=C2)C=C1)N[C@H](C3=NC4=CC=CC=C4N3)CCCNC(CCl)=N.Cl |
1 Publications Citing Use of MCE
Summary
BB-Cl-Amidine hydrochloride is a peptidylarginine deminase (PAD) inhibitor [1] .
IC50 & Target
PAD [1] .
In Vivo
Treatment with BB-Cl-amidine subtly reduces splenomegaly in MRL/lpr mice, while there is a trend towards increased circulating levels of anti-NET antibodies with PAD inhibitor treatment. However, neither PAD inhibitor affected body weight or total IgG levels. Indeed, treatment with both Cl-amidine and BB-Cl-amidine significantly improves endothelium-dependent vasorelaxation. The BB-Cl-amidine group also shows a strong trend towards downregulation of IRGs. Treatment with either Cl-amidine or BB-Cl-amidine significantly improves muzzle alopecia, in many cases preventing it entirely [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | MRL/lpr mice [1] . |
| Dosage: | 1 mg/kg. |
| Administration: | Subcutaneous injection daily from 8 to 14 weeks of age. |
| Result: | Significantly improved endothelium-dependent vasorelaxation and showed a strong trend towards downregulation of IRGs. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 201.44 mM )
H 2 O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.0144 mL | 10.0719 mL | 20.1438 mL |
| 5 mM | 0.4029 mL | 2.0144 mL | 4.0288 mL |
| 10 mM | 0.2014 mL | 1.0072 mL | 2.0144 mL |